Growth Hormone & Igf Research最新文献

{"title":"Paradoxical GH increase during oral glucose load may predict overall remission in acromegalic patients","authors":"Hakan Düğer ,&nbsp;Hayri Bostan ,&nbsp;Hilal Yıldırım Deryol ,&nbsp;Narin Nasıroğlu İmga ,&nbsp;Bekir Uçan ,&nbsp;Murat Çalapkulu ,&nbsp;Sema Hepşen ,&nbsp;Pınar Akhanlı ,&nbsp;Ümran Gül ,&nbsp;Muhammed Erkam Sencar ,&nbsp;Erman Çakal ,&nbsp;Şeyda Özdemir ,&nbsp;Muhammed Kızılgül","doi":"10.1016/j.ghir.2022.101501","DOIUrl":"10.1016/j.ghir.2022.101501","url":null,"abstract":"<div><h3>Background</h3><p>The nadir growth hormone (nGH) during the oral glucose tolerance test<span><span> (OGTT) is the gold standard method for diagnosing acromegaly. A paradoxical growth hormone (GH) response to oral glucose (OG) in acromegaly can be observed. The role of the paradoxical GH response on how the patients with acromegaly respond to the </span>treatment has been addressed in few studies. The aim of this study was to investigate the association between glucose-dependent growth hormone results and and the responses of acromegalic patients to surgical and/or medical therapy following surgery.</span></p></div><div><h3>Material and methods</h3><p><span>This retrospective cohort study included patients with acromegaly who underwent surgery (</span><em>n</em> = 189) or received primary medical treatment (<em>n</em><span> = 9). The mean age was 50.44 ± 12.81 years (M/F: 84/114). The patients were grouped into paradoxical (GH-P) and non-paradoxical (GH-nP) according to GH response to OG and were compared in terms of clinical and pathological features, pituitary tumor size, invasiveness, biochemical profiles, and how they responded to the treatment.</span></p></div><div><h3>Results</h3><p>The mean age, gender distribution, and basal tumor diameter were all similar in both groups (<em>p</em><span> &gt; 0.05). The GH-P group had a higher remission rate in response to medical therapy followed by surgery (83% vs. 55%; </span><em>p</em> <em>=</em> 0.026). Although a higher surgical remission rate in favor of GH-P was observed, it did not reach statistical significance (63% vs. 48%; <em>p</em> <em>=</em> 0.059). Overall treatment response rates were also higher in the GH-P group compared to the GH-nP group (89% vs. 71%; <em>p</em> <em>=</em> 0.005).</p></div><div><h3>Conclusion</h3><p>A paradoxical GH response to OG load may help to predict the response to medical treatment in patients with acromegaly.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"67 ","pages":"Article 101501"},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40378907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between gestational diabetes mellitus and bioavailability of insulin-like growth factors and role of their binding proteins","authors":"Kateřina Anderlová ,&nbsp;Anna Cinkajzlová ,&nbsp;Patrik Šimják ,&nbsp;Jana Kloučková ,&nbsp;Helena Kratochvílová ,&nbsp;Zdeňka Lacinová ,&nbsp;Věra Toušková ,&nbsp;Hana Krejčí ,&nbsp;Miloš Mráz ,&nbsp;Antonín Pařízek ,&nbsp;Martin Haluzík ,&nbsp;Michal Kršek","doi":"10.1016/j.ghir.2022.101511","DOIUrl":"10.1016/j.ghir.2022.101511","url":null,"abstract":"<div><h3>Objective</h3><p>Insulin-like growth factors (IGFs) are involved in regulating growth and metabolism and increase insulin sensitivity, improve glucose metabolism, and are potentially related to gestational diabetes mellitus (GDM) and its complications for mothers and fetuses.</p></div><div><h3>Design</h3><p>This study aimed to assess serum levels and cord blood levels of IGF system components in pregnant women with (39 participants) and without GDM (22 participants). Blood samples were obtained at 28–32 and 36–38 weeks of gestation and 6–12 months after delivery. Cord blood samples were obtained during delivery. Results between both groups as well as between single visits were statistically compared.</p></div><div><h3>Results</h3><p>Both IGF1 and IGF2 maternal serum levels did not differ between the GDM and non-GDM groups. However, levels of IGF-binding proteins (IGFBPs) were different. IGFBP4 levels were decreased during pregnancy and after delivery in women with GDM, while IGFBP7 levels were increased during pregnancy in women with GDM. Cord blood IGFBP3 and IGFBP7 levels were increased (<em>p</em> &lt; 0.001 for IGFBP3, <em>p</em> = 0.003 for IGFBP7), while IGFBP4 levels were decreased (p &lt; 0.001) in the GDM group compared with the non-GDM group.</p></div><div><h3>Conclusions</h3><p>Although IGF levels did not differ, changes in their function level could still persist possibly because of the effects of the binding proteins, especially their promoting or inhibitory effects on IGFs. These results should be considered in interpretation of IGF levels.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"67 ","pages":"Article 101511"},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1096637422000685/pdfft?md5=c03dde2ea02b742dcc8d21ea230f605b&pid=1-s2.0-S1096637422000685-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33518112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of 18 months of GH replacement on cardiovascular risk factors and quality of life in GH deficient adults; a randomized controlled trial using a fixed very low and a standard dose of GH","authors":"Galina Götherström,&nbsp;Gudmundur Johannsson,&nbsp;Johan Svensson","doi":"10.1016/j.ghir.2022.101510","DOIUrl":"10.1016/j.ghir.2022.101510","url":null,"abstract":"<div><h3>Objective</h3><p>Little is known of the effects of a fixed very low dose of growth hormone (GH) replacement on cardiovascular risk factors, bone mass, muscle strength and quality of life (QoL) in hypopituitary patients.</p></div><div><h3>Design/patients/methods</h3><p><span>This was an open-label randomized study performed at a single center. Consecutive hypopituitary patients with adult onset GH deficiency (GHD) and BMI ≥ 27 kg/m</span>² were randomized to receive a very low fixed dose of GH (LG, <em>n</em> = 9) or a standard dose of GH (SG, n = 9). Body composition, glucose and lipid metabolism, bone mineral content (BMC) and density (BMD), muscle strength, and QoL were measured at baseline and after 6, 12 and 18 months.</p></div><div><h3>Results</h3><p><span>The fixed GH dose in LG was 0.1 mg/day. In SG, the mean baseline GH dose of 0.13 mg/day was gradually increased to 0.31 mg/day at study end. Lean body mass<span> (LBM) as measured using DEXA as well as total body water (TBW) and extracellular water (ECW) were increased only in SG (</span></span><em>P</em> &lt; 0.01, <em>P</em><span> &lt; 0.05, and P &lt; 0.01 vs. LG, respectively). There were no between-groups differences in BMD, BMC, insulin sensitivity<span>, lipids, or muscle strength. Finally, although not significant compared with SG, a sustained improvement in QoL was seen in LG according to the QoL-AGHDA questionnaire.</span></span></p></div><div><h3>Conclusion</h3><p><span>In this pilot study, a fixed very low GH dose improved QoL in GHD adults without any induction of fluid retention. Other effects were comparable to those produced by the standard GH dose. Replacement with a very low GH dose could therefore be a treatment option in hypopituitary patients, especially </span>in patients who do not tolerate higher GH dosage.</p><p><em>Trial registration</em></p><p>This study is registered at <span>ClinicalTrials.gov</span><svg><path></path></svg>, EU-nr 2009–016783-37.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"67 ","pages":"Article 101510"},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10416387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth hormone inhibits adipogenic differentiation and induces browning in bovine subcutaneous adipocytes","authors":"Tingting Li,&nbsp;Hui Bai,&nbsp;Haoyuan Fang,&nbsp;Liang Yang,&nbsp;Peishi Yan","doi":"10.1016/j.ghir.2022.101498","DOIUrl":"10.1016/j.ghir.2022.101498","url":null,"abstract":"<div><h3>Objective</h3><p>It is well established that growth hormone (GH) has the ability to stimulate lipolysis<span>. The effects of GH on adipocyte differentiation and browning have not been clearly described. Therefore, the present study aimed to elucidate the role of GH in the differentiation and browning of bovine subcutaneous adipocytes as well as its underlying molecular mechanisms.</span></p></div><div><h3>Methods</h3><p>We first treated bovine subcutaneous preadipocytes<span><span> with different concentrations (0, 10, 100, and 500 ng/mL) of GH for 8 days and measured lipid accumulation and gene expression. Afterward, we treated preadipocytes and mature adipocytes with 500 ng/mL GH and determined differentiation and browning-related indicators. Finally, we investigated the expression of </span>STAT5B in both preadipocytes and mature adipocytes after GH treatment.</span></p></div><div><h3>Results</h3><p><span><span>We demonstrated that GH inhibited lipid accumulation and decreased the expression levels of adipogenic key genes (SCD1, SREBP1, PPARγ, and CEBPα) during adipocyte differentiation. Moreover, we observed that the inhibitory effect of GH on the early stage of adipocyte differentiation (0–2 days) was stronger than that on the later stage of adipocyte differentiation (2–8 days). We also found that GH promoted the expression levels of browning-related genes such as </span>uncoupling protein 1 (UCP1) in mature adipocytes. Concurrently, GH promoted </span>mitochondrial biogenesis and increased the expression levels of mitochondrial biogenesis-related genes. In addition, GH promoted phosphorylation of signal transducers and activator of transcription 5 b (STAT5B) and contributed to translocation of STAT5B to nucleus. After blocking the expression of STAT5B protein, GH weakened the inhibition of adipogenic key genes and reduced the promotion of browning-related genes in bovine subcutaneous adipocytes.</p></div><div><h3>Conclusions</h3><p>GH can inhibit adipocyte differentiation and promote adipocyte browning by regulating STAT5B in bovine subcutaneous adipocytes.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101498"},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40639236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do neurosteroids have impact on depression and cognitive functions in cases with acromegaly?","authors":"Esra Hatipoglu ,&nbsp;Yalcin Hacioglu ,&nbsp;Yeliz Polat ,&nbsp;Hilmi Furkan Arslan ,&nbsp;Sena Oner ,&nbsp;Ozlem Balci Ekmekci ,&nbsp;Mutlu Niyazoglu","doi":"10.1016/j.ghir.2022.101496","DOIUrl":"10.1016/j.ghir.2022.101496","url":null,"abstract":"<div><h3>Objective</h3><p>Neurosteroids<span> (NSs) are a distinct hormone group and, they are known for their contribution into the status of mood and cognitive functions. Whether they are also involved in the mood disturbances and cognition in acromegaly is not known. Herein we aimed to evaluate the relation of mood status and cognitive functions with the NS levels in cases with acromegaly.</span></p></div><div><h3>Design</h3><p><span>A total of 33 cases with acromegaly composed the acromegaly group (AG) and, 30 age and gender-matched cases without acromegaly composed the control group (CG). The levels of Allopregnanolone (AP), </span>pregnenolone<span><span> (PRG), 24S-hydroxycholesterol (24OHC), dehydroepiandrosterone (DHEA), </span>dehydroepiandrosterone sulfate<span><span> (DHEAS), androsterone (ADT), GH and IGF-1 were measured in each group. </span>Beck Depression Inventory (BDI) was used to assess depressive symptoms, whereas an extensive neuropsychological assessment with several neurocognitive tests were carried out for each subject by an experienced psychologist.</span></span></p></div><div><h3>Results</h3><p>Cases with acromegaly had lower 24OHC and DHEA levels (<em>p</em> = 0.002 and <em>p</em><span> = 0.007, respectively) in comparison to CG. Of the cognitive functions time to complete 1 s Series was significantly higher and, the scores on Switching Verbal Fluency Test, Boston Naming Test (BNT)-semantic and BNT-phonological, the highest learning point of Oktem Verbal Memory Processes </span><em>Test (</em>VMPT) were significantly lower in cases with acromegaly in comparison to those in controls (<em>p</em> = 0.004, <em>p</em> = 0.01, <em>p</em> &lt; 0.001, <em>p</em> = 0.02 and <em>p</em> = 0.05, respectively). KAS-perseveration errors were higher in CG (<em>p</em> = 0.03). In AG the levels of AP were negatively correlated with the scores on Months backward Test (MBT), Animal Naming Test, Construction, BNT-spontaneous and positively correlated with BNT-incorrect answers; PRG was positively correlated with VMPT-retention scores, ADT was negatively correlated with MBT and 3 s Series scores, DHEAS was positively correlated with VMPT-the highest learning point whereas it was negatively correlated with MBT scores. Additionally, the scores on BDI were positively correlated with DHEA levels in AG.</p></div><div><h3>Conclusion</h3><p>Cognitive changes may be encountered in acromegaly and, neurosteroids may contribute to the changes in certain cognitive functions.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101496"},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40602560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A consensus on optimization of care in patients with growth hormone deficiency and mild traumatic brain injury","authors":"Kevin C.J. Yuen ,&nbsp;Brent Masel ,&nbsp;Michael S. Jaffee ,&nbsp;Gregory O'Shanick ,&nbsp;Tamara L. Wexler ,&nbsp;Kent Reifschneider ,&nbsp;Randall J. Urban ,&nbsp;Sophie Hoang ,&nbsp;Nicky Kelepouris ,&nbsp;Andrew R. Hoffman","doi":"10.1016/j.ghir.2022.101495","DOIUrl":"10.1016/j.ghir.2022.101495","url":null,"abstract":"<div><h3>Objective/design</h3><p>Approximately 2.9 million children and adults in the US experience traumatic brain injuries (TBIs) annually, most of which are considered mild. TBI can induce varying consequences on pituitary function, with growth hormone deficiency (GHD) among the more commonly reported conditions. Panels of pediatric and adult endocrinologists, neurologists, physical medicine and rehabilitation specialists, and neuropsychologists convened in February and October 2020 to discuss ongoing challenges and provide strategies for detection and optimal management of patients with mild TBI and GHD.</p></div><div><h3>Results</h3><p>Difficulties include a low rate of seeking medical attention in the population, suboptimal screening tools, cost and complexity of GHD testing, and a lack of consensus regarding when to test or retest for GHD. Additionally, referrals to endocrinologists from other specialists are uncommon. Recommendations from the panels for managing such patients included multidisciplinary guidelines on the diagnosis and management of post-TBI GHD and additional education on long-term metabolic and probable cognitive benefits of GH replacement therapy.</p></div><div><h3>Conclusion</h3><p>As patients of all ages with mild TBI may develop GHD and/or other pituitary deficiencies, a multidisciplinary approach to provide education to endocrinologists, neurologists, neurosurgeons, traumatologists, and other providers and guidelines for the early identification and management of persistent mild TBI-related GHD are urgently needed.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101495"},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1096637422000521/pdfft?md5=acccc65b7fe6b7d99a90ff1d5754abe5&pid=1-s2.0-S1096637422000521-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40675614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The regulation of proliferation and apoptosis in hepatocellular carcinoma via insulin-like growth factor 1 receptor","authors":"Guanjun Xu,&nbsp;Jiesheng Chu,&nbsp;Yu Shi,&nbsp;Longzhang Huang,&nbsp;Jingzhong Fu","doi":"10.1016/j.ghir.2022.101499","DOIUrl":"10.1016/j.ghir.2022.101499","url":null,"abstract":"<div><h3>Objectives</h3><p><span><span>Insulin-like growth factor 1 receptor (IGF-1R) is a transmembrane tyrosine kinase receptor of the </span>insulin receptor family. Its expression is consistently increased in hepatocellular carcinoma (HCC) tissue, and it participates in </span>hepatic carcinogenesis<span>. Targeting IGF-1R may be a potential therapeutic approach against hepatocellular carcinoma. This study therefore aimed to explore the effect of IGF-1R on hepatocellular carcinoma cells.</span></p></div><div><h3>Methods</h3><p><span>IGF-1R silencing cell lines were established by small-interfering RNAs in hepatocellular carcinoma cell line SMMC7721, after which the proliferation, invasion, and </span>apoptosis<span><span> of SMMC7721 was evaluated. The activation of the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) signaling pathway and the expression of bone morphogenetic protein (BMP)-2 and BMP-7 were measured using </span>Western blot analysis.</span></p></div><div><h3>Results</h3><p>The results indicated that the knockdown of IGF-1R can inhibit the proliferation and invasion of HCC and promote the apoptosis of SMMC7721 by inhibiting the PI3K/AKT signaling pathway. Furthermore, depletion of IGF-1R was found to suppress the expression of BMP-2 and BMP-7.</p></div><div><h3>Conclusions</h3><p>The findings suggest that IGF-1R plays an important role in the progression of HCC. Therefore, IGF-1R is a potential target for the treatment of HCC in clinic.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101499"},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33455605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of long-acting growth hormone treatment on endogenous growth hormone secretion in prepubertal patients with idiopathic short stature: A preliminary study","authors":"Han Saem Choi,&nbsp;Ahreum Kwon,&nbsp;Junghwan Suh,&nbsp;Kyungchul Song,&nbsp;Hyun Wook Chae,&nbsp;Ho-Seong Kim","doi":"10.1016/j.ghir.2022.101486","DOIUrl":"10.1016/j.ghir.2022.101486","url":null,"abstract":"<div><p><span>Long-acting growth hormone (LAGH) is emerging to be a new preparation for treatment of short stature. We aimed to determine whether 12-month treatment with LAGH </span>in patients<span><span> with idiopathic short stature has an effect on the nocturnal endogenous growth hormone (GH) secretion and metabolic consequences and efficacy. Participants included 10 GH-naïve prepubertal children with idiopathic short stature (ISS). One patient was withdrawn due to own decline during study. Participants were randomized on a 1:1 ratio to receive either a daily GH (0.37 mg/kg/week) or once-weekly LAGH (0.7 mg/kg/week) over a 12-month period. Nocturnal endogenous GH secretory profiles obtained from 12-h blood samplings at 30-min interval were assessed at baseline and 2 weeks after the completion of GH treatment. Post-treatment changes in height velocity, height standard deviation score (SDS), metabolic parameters, and adverse events were measured. A total of 4 patients received LAGH, and 5 patients received daily GH. Nocturnal endogenous GH secretory profiles, such as mean </span>serum GH concentrations, frequency, amplitude, interpulse interval of spontaneous GH secretory bursts, and mass of GH released per secretory burst were similar at baseline and after 12-month treatment in both groups. The efficacy and safety after LAGH treatment for 12 months were similar to those of daily GH. In conclusions, these findings indicated that LAGH does not suppress endogenous GH secretion, and can be used for treatment of non-GH deficient short stature with similar efficacy and safety compared to daily GH. These may contribute to define and develop treatment and follow-up protocols for LAGH use in ISS patients.</span></p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101486"},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40626995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of metformin on thyroid cancer risk in patients with acromegaly: A preliminary observational study","authors":"Cem Sulu ,&nbsp;Ayyuce Begum Bektas ,&nbsp;Suleyman Sami Guzel ,&nbsp;Kubilay Tay ,&nbsp;Serdar Sahin ,&nbsp;Emre Durcan ,&nbsp;Hande Mefkure Ozkaya ,&nbsp;Pinar Kadioglu","doi":"10.1016/j.ghir.2022.101484","DOIUrl":"10.1016/j.ghir.2022.101484","url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate the role of metformin<span><span> on thyroid cancer risk </span>in patients<span> with acromegaly.</span></span></p></div><div><h3>Methods</h3><p>Medical charts of 534 patients with acromegaly that were followed-up between 1983 and 2019 were reviewed. Patients with follow-up duration at least 6 months were included. Cohort entry was defined as first visit date. The date of each case's thyroid cancer diagnosis was defined as index date. Patients were followed until the index date, death, or last visit date, whichever came first. Nested case-control study design was selected to evaluate the association between metformin and the thyroid cancer risk in patients with acromegaly.</p></div><div><h3>Results</h3><p>291 patients with acromegaly were included into final analysis. The mean age at acromegaly diagnosis was 42.3 ± 1.3 years. The median follow-up duration was 76 [34–132] months. Among 291 patients, 13 patients (4.5%) had thyroid cancer. Thirty-one percent (<em>n</em> = 92) of the patients used metformin for 6 months or longer. One standard deviation (SD) increase in average growth hormone increased the odds of having thyroid cancer by 1.164 folds (<em>p</em> = 0.017). One SD increase of the average insulin-like growth factor 1 to upper limit of normal ratio increased the odds of having thyroid cancer by 1.201 folds (<em>p</em> = 0.004). If a patient used metformin for at least 6 months, the odds to have thyroid cancer was decreased, multiplied by 0.62 with a 95% confidence interval of [0.47, 0.83] (<em>p</em> = 0.0013). The risk of thyroid cancer decreased with increasing duration of metformin use.</p></div><div><h3>Conclusion</h3><p>Metformin may decrease the thyroid cancer risk in patients with acromegaly.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101484"},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40531049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acromegaly-related cutis verticis gyrata","authors":"João Roque,&nbsp;Pedro Marques","doi":"10.1016/j.ghir.2022.101497","DOIUrl":"10.1016/j.ghir.2022.101497","url":null,"abstract":"<div><h3>Objective</h3><p><span>Acromegaly is a disorder caused by hypersecretion of growth hormone (GH), resulting in excessive levels of insulin-like growth factor 1 (IGF-1), and almost always due to a </span>pituitary tumor<span><span><span><span>. It is classically associated with acral enlargement, prominent facial features and soft tissue overgrowth. </span>Skin manifestations include </span>hirsutism<span><span>, acne, skin tags, </span>oily skin<span> and acanthosis nigricans. However, other uncommon dermatological features, such as </span></span></span>cutis verticis gyrata<span> (CVG), may also occur. Here, we review acromegaly-related CVG aiming to raise awareness for its possible occurrence in this setting, and we discuss its pathophysiology, presentation, management and differential diagnosis.</span></span></p></div><div><h3>Design</h3><p>A comprehensive literature search regarding CVG, particularly CVG related to acromegaly, has been carried out. Case reports, original studies and review papers, were considered.</p></div><div><h3>Results</h3><p><span>CVG is a rare benign skin lesion characterized by thickened and folded </span>scalp<span>, resembling the brain gyri and sulci. The diagnosis of CVG mainly relies on clinical examination, although tissue biopsy may be necessary in case of uncertain etiology. In acromegaly, CVG appears to be driven by the trophic effects of GH and IGF-1 on skin and soft tissues. While CVG is uncommon in acromegaly, it seems to occur more frequently in male patients. The management of acromegaly-related CVG essentially relies on controlling the serum levels of GH and IGF-1. Surgical skin procedures should be reserved for patients with severe aesthetic distress, after achieving the best possible control of acromegaly.</span></p></div><div><h3>Conclusions</h3><p>CVG is a rare manifestation of acromegaly that may allow an earlier diagnosis and a swifter treatment of these patients, which in turn may improve or entirely reverse such remarkable skin lesions.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101497"},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40675743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}